7 / 24
Le DT, et al.
Science.
2017;357(6349):409-413.
PD-1 Inhibition
Effective in MSI-High
Non-CRC Cancers
MSI-high/dMMR
across 12 tumor types
N = 86
•
Aprox. 1% mPCA
MSI-H/dMMR (IHC, PCR, NGS)
•
Pembrolizumab FDA
approved for MSI-H/dMMR
FDA, United States Food & Drug Administration; IHC,
immunohistochemistry; PCR, polymerase chain reaction;
NGS, next generation sequencing
BIOMARKERS IN 2
nd
line
ASCO 2018 Recommendation